← Back to Search

Other

Protein Supplement + Urolithin A for Muscle Atrophy

N/A
Recruiting
Led By Stuart Phillips
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7, day 14, day 28, day 35; integrated synthesis rates reported for day 7-14, day 14-28; day 28-35
Awards & highlights

Summary

This trial will investigate if Urolithin A can help prevent muscle decline during illness or injury when people can't use their muscles.

Who is the study for?
This trial is for healthy, non-smoking men aged 18-30 with a BMI of 20-30 kg/m^2. Participants must not have orthopedic issues affecting the knee, gastrointestinal conditions, excessive alcohol use, or allergies to study ingredients. They can't be on certain medications or supplements that affect muscle health.Check my eligibility
What is being tested?
The study tests if adding Urolithin A to a protein supplement helps maintain muscle health during periods when participants can't use their muscles due to wearing a knee brace. It compares the effects of just protein supplementation against protein with Urolithin A.See study design
What are the potential side effects?
Potential side effects are not detailed in the provided information but could include digestive discomfort given that individuals with existing gastrointestinal conditions are excluded from participation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 7, day 14, day 28, day 35; integrated synthesis rates reported for day 7-14, day 14-28; day 28-35
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 7, day 14, day 28, day 35; integrated synthesis rates reported for day 7-14, day 14-28; day 28-35 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in maximal mitochondrial respiration (rate of oxygen flux) and mitochondrial ADP [adenosine diphosphate] sensitivity (Oroboros O2k)
Secondary outcome measures
Muscle protein fractional synthetic rate
Muscle strength (Biodex)
Quadriceps muscle size

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Protein supplement with Urolithin AExperimental Treatment1 Intervention
Group II: Protein supplementActive Control1 Intervention

Find a Location

Who is running the clinical trial?

McMaster UniversityLead Sponsor
896 Previous Clinical Trials
2,610,206 Total Patients Enrolled
Stuart PhillipsPrincipal InvestigatorMcMaster University

Media Library

Protein supplement (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05814705 — N/A
Healthy Subjects Research Study Groups: Protein supplement with Urolithin A, Protein supplement
Healthy Subjects Clinical Trial 2023: Protein supplement Highlights & Side Effects. Trial Name: NCT05814705 — N/A
Protein supplement (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05814705 — N/A
~12 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top